ProMACE-CytaBOM regimen

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Synonyms and keywords:Prednisone-Methotrexate-Adriamycin-Cytoxan-Etoposide-Cytarabine-Bleomycin-Oncovin-Methotrexate Regimen; ProMACE-CytaBOM Regimen

Overview

ProMACE-CytaBOM regimen refers to a regimen consisting of a non-cross resistant regimen consisting of prednisone, methotrexate, doxorubicin, cyclophosphamide and etoposide (ProMACE) alternating with cytarabine, bleomycin, vincristine (oncovin) and methotrexate (CytaBOM), used to treat aggressive forms of non-Hodgkin’s lymphoma^[1]^[2]

Regimen

ProPrednisone

MMethotrexate

ADoxorubicin (Adriamycin)

CytaCyclophosphamide

EEtoposide

CytaCytarabine

BBleomycin

OVincristine (Oncovin)

MMethotrexate

Indications

Non-Hodgkin lymphoma^[1]

References

↑ ^1.0 ^1.1 Isogai R, Kawada A, Hashimoto K, Aragane Y, Tezuka T, Maeda Y; et al. (2004). “Nasal-type NK/T-cell lymphoma successfully treated with ProMACE-CytaBOM therapy”. Dermatology. 209 (3): 243–5. doi:10.1159/000079901. PMID 15459544.
↑ “NCI Thesaurus”.

[pmid15459544-1] 1.0 ^1.1 Isogai R, Kawada A, Hashimoto K, Aragane Y, Tezuka T, Maeda Y; et al. (2004). “Nasal-type NK/T-cell lymphoma successfully treated with ProMACE-CytaBOM therapy”. Dermatology. 209 (3): 243–5. doi:10.1159/000079901. PMID 15459544.

[2] “NCI Thesaurus”.

[1]

[2]